Cargando…
A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC
Sorafenib is used to treat digestive system tumors in patients who do not respond to or cannot tolerate surgery. However, the roles and inhibitory mechanisms of sorafenib against hepatocellular carcinoma (HCC) are unclear. Differentially expressed genes in tissues from responders and nonresponders t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256406/ https://www.ncbi.nlm.nih.gov/pubmed/35799605 http://dx.doi.org/10.1155/2022/7257738 |
_version_ | 1784741105723506688 |
---|---|
author | Liu, Xiang Zeng, Jian Li, Huanyu Li, Feng Jiang, Bin Zhao, Ming Liu, Zhuo Li, Ruineng Ma, Tiexiang |
author_facet | Liu, Xiang Zeng, Jian Li, Huanyu Li, Feng Jiang, Bin Zhao, Ming Liu, Zhuo Li, Ruineng Ma, Tiexiang |
author_sort | Liu, Xiang |
collection | PubMed |
description | Sorafenib is used to treat digestive system tumors in patients who do not respond to or cannot tolerate surgery. However, the roles and inhibitory mechanisms of sorafenib against hepatocellular carcinoma (HCC) are unclear. Differentially expressed genes in tissues from responders and nonresponders to sorafenib were investigated using the HCC GSE109211 data set. Biological functions and mechanisms were studied using the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes databases. The expression levels of differential expressed target genes were identified in HCC tissues, using The Cancer Genome Atlas database, and their prognostic and diagnostic values were explored using survival and receiver operating characteristic curve analysis. A nomogram and risk model of sorafenib-response target genes enabled the evaluation of the prognosis of patients with HCC. The relationship between risk scores and levels of infiltrating immune cells was visualized via correlation analysis. We identified 1620 sorafenib-response target genes involved in the PPAR signaling pathway, antigen processing and presentation, and ferroptosis. SLC41A3, SEC61A1, LRP4, PPM1G, and HSP90AA1 were independent risk factors for a poor prognosis for patients with HCC and had diagnostic value. A risk model based on SLC41A3, SEC61A1, LRP4, PPM1G, and HSP90AA1 expression showed that patients with HCC in the high-risk group had a worse prognosis. Consensus-clustering analysis (performed with K set to 2) distinguished two clusters (the cluster 1 and cluster 2 groups). Patients in cluster 1 survived significantly longer than those in cluster 2. The risk score correlated with the levels of T cells, cytotoxic lymphocytes, CD8(+) T cells, macrophages, memory B cells, follicular helper T cells, and other immune cells. The high risk based on the sorafenib-response targets SLC41A3, SEC61A1, LRP4, PPM1G, and HSP90AA1 represented the poor prognosis for patients with HCC and significantly correlated with the levels of immune infiltrating cells in HCC. |
format | Online Article Text |
id | pubmed-9256406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-92564062022-07-06 A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC Liu, Xiang Zeng, Jian Li, Huanyu Li, Feng Jiang, Bin Zhao, Ming Liu, Zhuo Li, Ruineng Ma, Tiexiang J Oncol Research Article Sorafenib is used to treat digestive system tumors in patients who do not respond to or cannot tolerate surgery. However, the roles and inhibitory mechanisms of sorafenib against hepatocellular carcinoma (HCC) are unclear. Differentially expressed genes in tissues from responders and nonresponders to sorafenib were investigated using the HCC GSE109211 data set. Biological functions and mechanisms were studied using the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes databases. The expression levels of differential expressed target genes were identified in HCC tissues, using The Cancer Genome Atlas database, and their prognostic and diagnostic values were explored using survival and receiver operating characteristic curve analysis. A nomogram and risk model of sorafenib-response target genes enabled the evaluation of the prognosis of patients with HCC. The relationship between risk scores and levels of infiltrating immune cells was visualized via correlation analysis. We identified 1620 sorafenib-response target genes involved in the PPAR signaling pathway, antigen processing and presentation, and ferroptosis. SLC41A3, SEC61A1, LRP4, PPM1G, and HSP90AA1 were independent risk factors for a poor prognosis for patients with HCC and had diagnostic value. A risk model based on SLC41A3, SEC61A1, LRP4, PPM1G, and HSP90AA1 expression showed that patients with HCC in the high-risk group had a worse prognosis. Consensus-clustering analysis (performed with K set to 2) distinguished two clusters (the cluster 1 and cluster 2 groups). Patients in cluster 1 survived significantly longer than those in cluster 2. The risk score correlated with the levels of T cells, cytotoxic lymphocytes, CD8(+) T cells, macrophages, memory B cells, follicular helper T cells, and other immune cells. The high risk based on the sorafenib-response targets SLC41A3, SEC61A1, LRP4, PPM1G, and HSP90AA1 represented the poor prognosis for patients with HCC and significantly correlated with the levels of immune infiltrating cells in HCC. Hindawi 2022-06-28 /pmc/articles/PMC9256406/ /pubmed/35799605 http://dx.doi.org/10.1155/2022/7257738 Text en Copyright © 2022 Xiang Liu et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Liu, Xiang Zeng, Jian Li, Huanyu Li, Feng Jiang, Bin Zhao, Ming Liu, Zhuo Li, Ruineng Ma, Tiexiang A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC |
title | A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC |
title_full | A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC |
title_fullStr | A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC |
title_full_unstemmed | A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC |
title_short | A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC |
title_sort | risk model based on sorafenib-response target genes predicts the prognosis of patients with hcc |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256406/ https://www.ncbi.nlm.nih.gov/pubmed/35799605 http://dx.doi.org/10.1155/2022/7257738 |
work_keys_str_mv | AT liuxiang ariskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc AT zengjian ariskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc AT lihuanyu ariskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc AT lifeng ariskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc AT jiangbin ariskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc AT zhaoming ariskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc AT liuzhuo ariskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc AT liruineng ariskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc AT matiexiang ariskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc AT liuxiang riskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc AT zengjian riskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc AT lihuanyu riskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc AT lifeng riskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc AT jiangbin riskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc AT zhaoming riskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc AT liuzhuo riskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc AT liruineng riskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc AT matiexiang riskmodelbasedonsorafenibresponsetargetgenespredictstheprognosisofpatientswithhcc |